| Project/Area Number |
23659427
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
KUBO Hiroshi 東北大学, 大学院・医学系研究科, 准教授 (20332504)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
不破 春彦 東北大学, 生命科学研究科, 准教授 (90359638)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 創薬 / 癌 / 海洋生物 / 薬剤反応性 / シグナル伝達 / 薬学 / マイクロアレイ / 薬理学 / トランスレーショナルリサーチ |
|---|
| Research Abstract |
The aim of this experiment is to elucidate the mechanisms of an anti-cancer effect of a novel marine natural compound, exiguolide. The cell cycle of cultured cancer cells was arrested with apoptotic cells death under incubation with exiguolide. Tumor growth was also attenuated by the treatment with exiguolide in the in vivo xenograft model in mice. Several kinases were involved in this anti-cancer effect. Then, we synthesized exiguolide analogues with modified structures. Some of the analogues had a similar anti-cancer effect in both in vitro and in vivo. These results will bring the basis for developing a new anti-cancer drug, which can be clinically applicable.
|
